Clinically, SETD2 mutations are most prevalent in clear cell renal carcinomas but are also less commonly seen in hematopoietic cancers, high-grade glioma, melanoma, and adenocarcinomas of the lung and gastrointestinal system (25). Here, SETD2 is linked to melanoma.